Search

Tetraferric tricitrate decahydrate

Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. … [A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]

Zolpidem

It is aimed for use in patients with difficulties initiating sleep. … Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia.

Ferric maltol

[A189291] Ferric maltol was initially granted FDA approval on July 25, 2019, for use in adults. … Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate

Choline salicylate

This drug is also a main ingredient in teething gels to relieve pains associated with tooth growth in the infant population [L2134]. … It is used to treat arthritis in both children and adults. This medicine can also be used for fever [L2129].

Vandetanib

Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. … On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

Oteracil

Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno". … It functions by blocking the enzyme orotate phosphoribosyltransferase (OPRT), which is involved in the production of 5-FU.

RG-7795

Ponatinib

Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

Vadadustat

[A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance … [L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371]

Polysorbate 20

It is also an excipient that stabilizes emulsions and suspensions in pharmaceutical products and lubricant in ophthalmic solutions. … Polysorbate 20 is a wetting agent in food products, as well as washing agent, stabilizer and solubilizer in labratory assays and industrial applications.